BWX Technologies IncRaised 2026 revenue guidance to $3.80B and reported solid Q2 results, reinforcing investment thesis.

BWX Technologies reported second-quarter 2026 sales of US$901.63 million and net income of US$89.01 million, raised its full-year 2026 revenue guidance to about US$3.80 billion, and declared a US$0.27 per-share quarterly dividend payable on September 4, 2026. The company also agreed to sell most of its medical business for up to US$800 million, sharpening its focus on core nuclear markets and advanced reactor technologies. The portfolio shift increases BWXT's exposure to government and commercial nuclear catalysts while reducing diversification if nuclear or defense spending were to slow. The raised guidance and solid quarterly results modestly reinforce the investment thesis centered on long-term U.S. defense and nuclear power spending, supported by a large multi-year backlog.
BWX Technologies IncRaised 2026 revenue guidance to $3.80B and reported solid Q2 results, reinforcing investment thesis.